These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19372440)

  • 1. Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: a clinical registry study and systematic review.
    Meseguer E; Mazighi M; Labreuche J; Arnaiz C; Cabrejo L; Slaoui T; Guidoux C; Olivot JM; Abboud H; Lapergue B; Raphaeli G; Klein IF; Lavallée PC; Amarenco P
    Stroke; 2009 Jun; 40(6):2104-10. PubMed ID: 19372440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
    Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
    JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of MRI-based selection for recombinant tissue plasminogen activator treatment: responder analysis of outcome in the 3-hour time window.
    Sølling C; Hjort N; Ashkanian M; Østergaard L; Andersen G
    Cerebrovasc Dis; 2009; 27(3):223-9. PubMed ID: 19176954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Hemorrhage Volume after Intravenous Thrombolysis.
    Shon SH; Heo SH; Kim BJ; Choi HY; Kwon Y; Yi SH; Lee JS; Kim YS; Kim HY; Koh SH; Chang DI
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2543-8. PubMed ID: 27444521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety assessment of alteplase in the treatment of stroke - gender differences.
    Lasek-Bal A; Puz P; Kazibutowska Z
    Neurol Res; 2014 Sep; 36(9):851-6. PubMed ID: 24620981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.
    Kent DM; Price LL; Ringleb P; Hill MD; Selker HP
    Stroke; 2005 Jan; 36(1):62-5. PubMed ID: 15569865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+intra-arterial thrombolysis.
    Mullen MT; Pisapia JM; Tilwa S; Messé SR; Stein SC
    Stroke; 2012 Sep; 43(9):2350-5. PubMed ID: 22811451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.
    Blum B; Wormack L; Holtel M; Penwell A; Lari S; Walker B; Nathaniel TI
    BMC Womens Health; 2019 Jan; 19(1):11. PubMed ID: 30651099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature.
    Edwards NJ; Kamel H; Josephson SA
    Stroke; 2012 Feb; 43(2):412-6. PubMed ID: 22156701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
    Fredwall M; Sternberg S; Blackhurst D; Lee A; Leacock R; Nathaniel TI
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2569-2574. PubMed ID: 27618196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms.
    Amaro S; Cánovas D; Castellanos M; Gállego J; Martí-Fèbregas J; Segura T; Chamorro A
    Int J Stroke; 2010 Aug; 5(4):325-8. PubMed ID: 20636718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review.
    Wang X; You S; Sato S; Yang J; Carcel C; Zheng D; Yoshimura S; Anderson CS; Sandset EC; Robinson T; Chalmers J; Sharma VK
    Stroke Vasc Neurol; 2018 Mar; 3(1):28-33. PubMed ID: 29600005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perfusion computed tomography to assist decision making for stroke thrombolysis.
    Bivard A; Levi C; Krishnamurthy V; McElduff P; Miteff F; Spratt NJ; Bateman G; Donnan G; Davis S; Parsons M
    Brain; 2015 Jul; 138(Pt 7):1919-31. PubMed ID: 25808369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the application of X-ray contrast agents impair the clinical effect of intravenous recombinant tissue-type plasminogen activator in acute ischemic stroke patients?
    Dzialowski I; Puetz V; Buchan AM; Demchuk AM; Hill MD;
    Stroke; 2012 Jun; 43(6):1567-71. PubMed ID: 22496336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.